MYO1E sirna

MYO1E siRNA (Human)

Cat. Num. AAA8212685

• Gene Names: MYO1E; FSGS6; MYO1C; HuncM-IC
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: MYO1E; MYO1E siRNA (Human); MYO1C; Unconventional myosin-Ie; Myosin-Ic; Unconventional myosin 1E; MYO1E sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: MYO1E siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 1108

• Applicable Applications for MYO1E sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human MYO1E gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for MYO1E sirna

siRNA to inhibit MYO1E expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 55956916
• NCBI GeneID: 4643
• NCBI Accession #: NP_004989.2
• NCBI GenBank Nucleotide #: NM_004998.3
• UniProt Accession #: Q12965; Q14778
• Molecular Weight: 127,062 Da
• NCBI Official Full Name: unconventional myosin-Ie
• NCBI Official Synonym Full Names: myosin IE
• NCBI Official Symbol: MYO1E
• NCBI Official Synonym Symbols: FSGS6; MYO1C; HuncM-IC
• NCBI Protein Information: unconventional myosin-Ie
• UniProt Protein Name: Unconventional myosin-Ie
• Protein Family: Unconventional myosin
• UniProt Gene Name: MYO1E
• UniProt Synonym Gene Names: MYO1C
• UniProt Entry Name: MYO1E_HUMAN

NCBI Description

This gene encodes a member of the nonmuscle class I myosins which are a subgroup of the unconventional myosin protein family. The unconventional myosin proteins function as actin-based molecular motors. Class I myosins are characterized by a head (motor) domain, a regulatory domain and a either a short or long tail domain. Among the class I myosins, this protein is distinguished by a long tail domain that is involved in crosslinking actin filaments. This protein localizes to the cytoplasm and may be involved in intracellular movement and membrane trafficking. Mutations in this gene are the cause of focal segmental glomerulosclerosis-6. This gene has been referred to as myosin IC in the literature but is distinct from the myosin IC gene located on chromosome 17. [provided by RefSeq, Jan 2012]

Uniprot Description

MYO1E: Myosins are actin-based motor molecules with ATPase activity. Unconventional myosins serve in intracellular movements. Their highly divergent tails bind to membranous compartments, which are then moved relative to actin filaments. Binds to membranes containing anionic phospholipids via its tail domain. Required for normal morphology of the glomerular basement membrane, normal development of foot processes by kidney podocytes and normal kidney function. In dendritic cells, may control the movement of class II-containing cytoplasmic vesicles along the actin cytoskeleton by connecting them with the actin network via ARL14EP and ARL14. Defects in MYO1E are the cause of focal segmental glomerulosclerosis type 6 (FSGS6). A renal pathology defined by the presence of segmental sclerosis in glomeruli and resulting in proteinuria, reduced glomerular filtration rate and progressive decline in renal function. Renal insufficiency often progresses to end-stage renal disease, a highly morbid state requiring either dialysis therapy or kidney transplantation. FSGS6 is a childhood-onset disorder resulting in nephrotic syndrome, which includes massive proteinuria, hypoalbuminemia, hyperlipidemia, and edema.

Protein type: Actin-binding; Motility/polarity/chemotaxis; Motor

Chromosomal Location of Human Ortholog: 15q21-q22

Cellular Component: adherens junction; cytoskeleton; cytoplasm; clathrin-coated endocytic vesicle; intercellular junction; myosin complex; actin cytoskeleton

Molecular Function: actin filament binding; microfilament motor activity; calmodulin binding; protein binding; motor activity; ATPase activity, coupled; phosphoinositide binding; ATP binding

Biological Process: nitrogen compound metabolic process; actin filament-based movement; post-embryonic hemopoiesis; in utero embryonic development; glomerular filtration; glomerular basement membrane development; platelet-derived growth factor receptor signaling pathway; endocytosis; vasculogenesis

Disease: Focal Segmental Glomerulosclerosis 6